The global Premature Ejaculation Treatment Market size was valued at US$ 1.5 Bn in 2017, and is expected to witness a CAGR of 8.7% over the forecast period (2018 – 2026).
Premature ejaculation also called as rapid ejaculation, premature climax or early ejaculation. It is a disorder, which causes early ejaculation of semen during sexual intercourse. Premature ejaculation is a very common problem, and its exact cause is not known. However, causes include early sexual experiences, sexual abuse, poor body image, depression, anxiety, abnormal hormone levels, inherited traits, inflammation and infection of the prostate or urethra, and worrying about premature ejaculation.
Frequent launches and approvals of novel premature ejaculation treatment products is expected to drive growth of the market
Key players in the market are focusing on launching new products, which in turn is expected to aid in growth of the market. For instance, in 2012, Absorption Pharmaceuticals, LLC launched its Promescent, an over-the-counter lidocaine-based spray, indicated for premature ejaculation. Furthermore, in 2013, Absorption Pharmaceuticals, LLC received patent for its Promescent, for premature ejaculation (PE) from the U.S. Patent and Trademark Office. The launches of novel drugs, which are indicated for the treatment of premature ejaculation is expected to fuel growth of the global premature ejaculation treatment market in the near future.
Increasing launches of novel products for the treatment of premature ejaculation is expected to fuel the global premature ejaculation treatment market growth. For instance, in 2016, Regent Pacific Group Limited, a Hong Kong-based investment group, launched its product, Fortacin in the U.K. Fortacin is a topical spray, which contains low doses of two anesthetics – lidocaine and prilocaine and is indicated for the treatment of premature ejaculation. Furthermore, increasing prevalence of premature ejaculation due to unhealthy lifestyle and various factors such as depression and hormonal imbalance is expected to rise demand for premature ejaculation treatment drugs. For instance, according to the data published by National Center for BioDrug Type Information in 2016, around 25.8% of male in China are suffering from premature ejaculation.
Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1956
Key players operating in the premature ejaculation treatment market include Regent Pacific Group Limited, Menarini Group, Furiex Pharmaceuticals, Inc., Absorption Pharmaceuticals, LLC, Ampio Pharmaceuticals, Inc., Aytu BioScience, NeuroHealing Pharmaceuticals Inc., and Dong-A Pharmaceutical Co., Ltd.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.